Physician Guidelines
MMF Clinical Trial
(Please read below before accessing the PDF version of the physician guidelines.)
These guidelines and the information they contain are copyrighted material of Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance ("FHCRC / SCCA"), all rights reserved. They are intended solely for the use of referring physicians who are involved in the care of patients who have had an hematopoietic stem cell transplant at FHCRC / SCCA. They may not be used for any other purpose, and FHCRC / SCCA disclaims all liability for the use of these guidelines except as expressly permitted by FHCRC / SCCA. No portion of these guidelines may be copied, displayed for redistribution to third parties for commercial purposes or for any non-permitted use without the prior written permission of FHCRC / SCCA.
These guidelines describe generally accepted practices for medical care after hematopoietic stem cell transplantation. Care has been taken to assure that the information in these guidelines is current and accurate based on the available literature and the experience of physicians and patients at FHCRC / SCCA. Recommendations in these guidelines must be implemented in a medically reasonable way that accounts for the specific situation of the individual patient. Recommendations for patients who are enrolled in specific protocols may differ from the recommendations in these guidelines and will be communicated separately. Questions concerning the recommendations in these guidelines or their application to particular patients should be directed to the LTFU office. See Section I of the guidelines for information on how to contact the LTFU office.
Contributions to these guidelines were made by Mary E. D. Flowers, M.D.; George McDonald, M.D.; Michael Boeckh, M.D.; Jean Sanders, M.D.; Joachim Deeg, M.D.; Jean Stern, M.S.R.D,; Leona Holmberg, M.D., Ph.D.; Mark Schubert, D.D.S.; and Paul J. Martin, M.D.
[PDF version of guidelines for physicians]
Fred Hutchinson Cancer Research Center is the coordinating center for this multi-site clinical trial. This is a randomized, double-blind trial to test whether the addition of MMF improves the efficacy of the systemic immunosuppressive regimen first used for treatment of chronic graft-versus-host disease. The Principal Investigator for this study is Paul J. Martin, M.D.
Patients must be identified through a participating transplant center or physician. Accrual is anticipated to continue through 2009.
Physicians interested in identifying a participating transplant center may call the study office, toll-free at (866) 809-4154.
